Caption: Structure of a HIV capsid (Left) Central slice view of a HIV virus-like particle with pore-forming toxin on the membrane (Middle) Atomic model of a HIV capsid (Right) Density map of HIV ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor ...

for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP). The FDA granted priority review, with a decision expected by 19 June 2025.

On February 18, 2025, Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a twice-yearly injectable HIV-1 capsid ...